SK Biopharm announced on the 28th that it has signed a pharmaceutical supply agreement worth 81,126,011,041 won with its U.S. subsidiary, SK Life Science, Inc.

The contract covers the supply of products to SK Life Science, Inc. for the sale of the novel epilepsy treatment drug 'cenobamate' in the U.S. market. The supply region is limited to locations designated by the subsidiary.

• *[Key Contract Details]**
• Contract Amount: Total USD 55,361,001.12
• Won Equivalent: 81,126,011,041 KRW (based on the exchange rate of 1,465.40 KRW/USD as of the contract date of July 28, 2026, excluding value-added tax)
• Contract Period: July 28, 2026 to July 29, 2026
• Payment Terms: Payment within 120 days after delivery

The contract amount represents 11.5% of SK Biopharm's recent revenue (706,740,960,308 KRW based on 2025 consolidated figures).

The company explained that this contract is an internal transaction with its U.S. subsidiary and will not be reflected in consolidated financial statement revenue. Additionally, it noted that the contract (order receipt) date was determined based on the Purchase Order approval date.